logowsbdaily | Mon, 26 Sep 2022 02:18:10 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Pfizer Inc.
(PFE)

Pfizer Inc.
235 East 42nd Street
New York, NY 10017
United States
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea... Read More

Summary & Charts

Price$ 44.08-0.49 (-1.1%)
Day's Range$ 43.58 - 44.56 
Previous Close$ 44.57
Market Cap$ 247.39B USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNYSE
IndustryDrug Manufacturers—General
SectorHealthcare
Volume18.87M
Avg. Volume (20 day)17.73M
Rel. Volume (20 day)1.06
Rel. Volume (3 month)1.06
RatingA+Strong Buy
DCFN/AStrong Buy
Debt/Equity123.64 %Buy
ROE36.35 %Buy
ROA17.63 %Neutral
P/E8.58 %Buy
P/B2.83 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Sep 23, 2022$ 44.44$ 44.56$ 43.58$ 44.08-0.4918,872,9261.061.06
Sep 22, 2022$ 43.67$ 45.00$ 43.52$ 44.57+0.6518,508,8081.061.041
Sep 21, 2022$ 44.81$ 44.98$ 43.90$ 43.92-0.8517,506,8581.010.96
Sep 20, 2022$ 45.00$ 45.27$ 44.44$ 44.77-0.6715,370,3120.890.845
Sep 19, 2022$ 45.68$ 45.88$ 44.78$ 45.44-0.5916,243,2440.940.882
Sep 16, 2022$ 46.09$ 46.62$ 45.64$ 46.03+0.0930,630,6191.781.644
Sep 15, 2022$ 46.11$ 46.29$ 45.70$ 45.94-0.2115,799,9210.950.861
Sep 14, 2022$ 46.20$ 46.41$ 45.78$ 46.15-0.0417,163,0261.040.93
Sep 13, 2022$ 47.13$ 47.32$ 46.02$ 46.19-1.5716,596,5401.020.90
Sep 12, 2022$ 48.08$ 48.35$ 47.69$ 47.76-0.0813,557,0570.840.71
Sep 09, 2022$ 47.20$ 47.99$ 47.10$ 47.84+0.7617,502,1741.040.90
Sep 08, 2022$ 46.02$ 47.12$ 45.87$ 47.08+0.9518,265,3261.010.94
Sep 07, 2022$ 45.70$ 46.21$ 45.38$ 46.13+0.3715,369,4430.850.792
Sep 06, 2022$ 45.96$ 46.44$ 45.53$ 45.76+0.0617,139,1000.960.88
Sep 02, 2022$ 46.74$ 46.80$ 45.53$ 45.70-0.9314,258,6350.800.732
Sep 01, 2022$ 45.14$ 46.65$ 45.14$ 46.63+1.4019,130,8091.070.982
Aug 31, 2022$ 46.01$ 46.29$ 45.13$ 45.23-0.6226,414,5541.491.353
Aug 30, 2022$ 46.34$ 46.35$ 45.80$ 45.85-0.3816,296,6800.950.84
Aug 29, 2022$ 46.38$ 46.69$ 46.12$ 46.23-0.5913,400,9390.770.691
Aug 26, 2022$ 47.62$ 47.96$ 46.70$ 46.82-1.0816,541,6460.940.842

News

The latest news about Pfizer Inc. (PFE).

Reuters | 2022-09-24 16:20:06
Pfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19.
CNBC Television | 2022-09-22 18:04:27
Aadil Zaman, Wall Street Alliance Group, joins 'Closing Bell: Overtime' to discuss three stocks: Alphabet, Microsoft and Pfizer.
Market Watch | 2022-09-22 06:51:18
Pfizer Inc. PFE, -1.90% said Thursday it has reached an agreement to supply up to six million treatment courses of its COVID antiviral Paxlovid to the Global Fund for low and middle-income countries. The company said it expects supply to be available starting in 2022, pending regulatory authorization or approval and based on demand from individual countries.
Seeking Alpha | 2022-09-20 23:24:20
From 2Q 2021 to 2Q 2022, Pfizer's net income increased by 78% YoY to $9.9 billion. As of 19 September 2022, Pfizer/BioNTech vaccine doses administered globally decreased from 858000 per day in the second quarter to 566000 per day in the third quarter.
Seeking Alpha | 2022-09-20 10:49:52
The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there are many opportunities in women's health drug development.
Seeking Alpha | 2022-09-20 10:04:38
Pfizer has expected 2022 sales of COMIRNATY remains at $32 billion and then $22 billion for PAXLOVID. A possible surge in Covid-19 cases in Fall of 2022 would mean improved sales of COMIRNATY and PAXLOVID, especially if the U.S. Government takes option to buy another 195 million vaccine doses.
Business Wire | 2022-09-20 10:00:00
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2022. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2022 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-01BMO1.5----22B----
2022-07-28BMO1.782.0414.6%------
2022-05-03BMO1.471.6713.6%22B26B15.74%
2022-02-08BMO0.851.0827.05%0.2T24B-89.13%
2021-11-02BMO1.081.3424.07%22B24B7.65%
2021-07-28BMO0.971.0710.3%23B19B-17.04%
2021-05-04BMO0.770.9320.77%14B15B7.6%
2021-02-02BMO0.480.42-12.5%6.7B5.9B-11.12%

Top Discussions

These are the top discussions over the last 24-hours that mention the PFE stock ticker symbol.


Unusual Option Activity

Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.

TypeStrikeExp DateDTEBidAskLastVolumeOpen InterestVol/OIIV
CALL$ 43.0009/29/224$ 1.43$ 1.59$ 1.4128221.270.43%
CALL$ 43.5009/29/224$ 1.09$ 1.15$ 0.90145443.300.37%
CALL$ 44.0009/29/224$ 0.76$ 0.84$ 0.778092293.530.35%
CALL$ 44.5009/29/224$ 0.53$ 0.61$ 0.566732962.270.35%
CALL$ 45.5009/29/224$ 0.21$ 0.25$ 0.215613931.430.33%
CALL$ 51.5009/29/224$ 0.01$ 0.02$ 0.04170632.700.55%
PUT$ 43.0009/29/224$ 0.33$ 0.37$ 0.3510,74228937.170.36%
CALL$ 44.0010/06/2211$ 1.08$ 1.18$ 1.124861532.400.34%
CALL$ 49.0010/06/2211$ 0.03$ 0.05$ 0.034162781.500.33%
CALL$ 54.0010/06/2211$ 0.00$ 0.03$ 0.04201434.670.51%
PUT$ 42.0010/06/2211$ 0.33$ 0.39$ 0.3796591.630.35%
CALL$ 46.0010/27/2232$ 0.80$ 0.93$ 0.821,1896717.750.31%
PUT$ 36.0010/27/2232$ 0.08$ 0.16$ 0.09406557.380.44%
PUT$ 40.0010/27/2232$ 0.39$ 0.47$ 0.4622121.830.36%
CALL$ 23.0001/19/23116$ 23.80$ 24.30$ 29.1590109.001.43%
CALL$ 40.0003/16/23172$ 6.00$ 6.25$ 5.902281331.710.34%
CALL$ 45.0003/16/23172$ 3.15$ 3.25$ 3.103741951.920.30%
CALL$ 47.5003/16/23172$ 2.11$ 2.24$ 2.175,7041,1235.080.29%
PUT$ 27.5003/16/23172$ 0.22$ 0.30$ 0.252,6243770.920.45%
CALL$ 50.0001/16/25844$ 4.65$ 5.55$ 5.403,8932,0201.930.29%
Last Updated: Sat, 24 Sep 2022 21:30 EST

Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Mon, 13 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.